Guide for Real-World Evidence
Real-world data (RWD) from electronic medical records, insurance claims, and disease registries have expanded what Biotechs can learn about patient outcomes. Turned into real-world evidence (RWE), this is fast becoming a go-to tool for Biotech companies to optimize asset valuation, inform strategy and support regulator and payer decisions.
Parexel Biotech has created this guide to simplify the nomenclature and types of real-world studies.
Related Insights
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025
Blog
Evidence planning for biotechs: Closing gaps to maximize value
Nov 4, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Related Insights
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025
Blog
Evidence planning for biotechs: Closing gaps to maximize value
Nov 4, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026